What is Roth Capital's Forecast for InfuSystem Q4 Earnings?

Key Points

• Roth Capital has lowered its Q4 2025 earnings estimate for InfuSystem to $0.05 per share, down from $0.06, while maintaining a "Strong-Buy" rating on the stock.
• The consensus estimate for InfuSystem's full-year earnings is currently $0.15 per share, with future estimates of $0.34 EPS for FY2026 and $0.50 EPS for FY2027.
• Institutional investors hold 71.13% of InfuSystem shares, indicating strong institutional interest with significant stakes recently acquired by various firms.

InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) - Equities research analysts at Roth Capital reduced their Q4 2025 earnings per share estimates for shares of InfuSystem in a research report issued on Tuesday, August 5th. Roth Capital analyst K. Bauser now anticipates that the company will earn $0.05 per share for the quarter, down from their previous estimate of $0.06. Roth Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for InfuSystem's current full-year earnings is $0.15 per share. Roth Capital also issued estimates for InfuSystem's Q2 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at $0.34 EPS and FY2027 earnings at $0.50 EPS.

INFU has been the subject of several other reports. B. Riley raised InfuSystem to a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen downgraded InfuSystem from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 14th.

InfuSystem Stock Up 17.4%

Shares of NYSE:INFU traded up $1.31 on Thursday, hitting $8.83. 654,482 shares of the company's stock were exchanged, compared to its average volume of 157,035. The firm's 50-day moving average is $6.11 and its 200 day moving average is $6.18. The company has a market capitalization of $185.57 million, a PE ratio of 147.19 and a beta of 1.81. InfuSystem has a 1-year low of $4.61 and a 1-year high of $9.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98.

Institutional Trading of InfuSystem

Institutional investors and hedge funds have recently made changes to their positions in the company. Nuveen Asset Management LLC lifted its holdings in shares of InfuSystem by 14.1% in the 4th quarter. Nuveen Asset Management LLC now owns 86,379 shares of the company's stock valued at $730,000 after purchasing an additional 10,647 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of InfuSystem by 67.9% in the 4th quarter. BNP Paribas Financial Markets now owns 6,844 shares of the company's stock valued at $58,000 after purchasing an additional 2,768 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of InfuSystem by 148.3% in the fourth quarter. Deutsche Bank AG now owns 27,671 shares of the company's stock valued at $234,000 after purchasing an additional 16,526 shares during the period. Two Sigma Investments LP increased its holdings in shares of InfuSystem by 40.4% in the fourth quarter. Two Sigma Investments LP now owns 36,252 shares of the company's stock valued at $306,000 after purchasing an additional 10,427 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of InfuSystem by 7.7% in the fourth quarter. Northern Trust Corp now owns 186,741 shares of the company's stock valued at $1,578,000 after purchasing an additional 13,333 shares during the period. 71.13% of the stock is owned by hedge funds and other institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.